Biotech Raptor (RPTP) plunged in early trading Monday after its drug candidate failed a trial in pediatric fatty liver disease. Raptor said its phase two trial of its candidate RP103 in nonalcoholic steatohepatitis (NASH) failed to meet its endpoint of a two-point improvement in a fatty-liver-disease scoring system, and no worsening of fibrosis, or scarring of the liver. “We’re disappointed with this outcome, given the paucity of treatment for
Biotech Intercept Pharmaceuticals (ICPT) announced Tuesday that it had hammered out a design for a phase three trial of its nonalcoholic steatohepatitis (NASH) treatment, but the stock sold off as the time frame looked longer than many investors expected. There’s no current treatment for NASH, a slow-acting disease in which fat buildup around the liver causes progressive scarring, which is why there was no previous model of a large clinical trial
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making investments to get part of NASH, a form of liver damage caused by accumulation of fat. Regulus said RG-125, a compound to treat nonalcoholic steatohepatitis (NASH) in patients with type II diabetes or